Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Buspirone
Drug ID BADD_D00316
Description Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs.[L4478] Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'.[A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA [A181751] and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety. It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate.[L7375] The potential use of buspirone in combination with [melatonin] in depression and cognitive impairment via promoting neurogenesis has also been investigated.[A181751]
Indications and Usage For the management of anxiety disorders or the short-term relief of the symptoms of anxiety, and also as an augmention of SSRI-treatment against depression.
Marketing Status Prescription; Discontinued
ATC Code N05BE01
DrugBank ID DB00490
KEGG ID D07593
MeSH ID D002065
PubChem ID 2477
TTD Drug ID D0U2OO
NDC Product Code Not Available
Synonyms Buspirone | N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide | Buspirone Hydrochloride | Hydrochloride, Buspirone | Gen-Buspirone | Gen Buspirone | Lin-Buspirone | Lin Buspirone | MJ-9022-1 | MJ 9022 1 | MJ90221 | Neurosine | Busp | Nu-Buspirone | Nu Buspirone | PMS-Buspirone | PMS Buspirone | Ratio-Buspirone | Ratio Buspirone | Anxut | Apo-Buspirone | Apo Buspirone | Buspar | Bespar | Novo-Buspirone | Novo Buspirone
Chemical Information
Molecular Formula C21H31N5O2
CAS Registry Number 36505-84-7
SMILES C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Emotional distress19.04.02.008--Not Available
Contusion15.03.01.008; 12.01.06.001; 24.07.06.001; 23.03.11.002--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Sticky skin23.03.03.019--Not Available
Eye pruritus06.04.05.006--Not Available
Ocular discomfort06.08.03.008--Not Available
Respiratory tract congestion22.02.07.003--Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Temperature intolerance08.01.09.022--Not Available
Nuchal rigidity15.05.04.005; 17.05.02.006--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Electrocardiogram change13.14.05.014--Not Available
Therapeutic reaction time decreased08.06.01.015--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Adverse drug reaction08.06.01.009--Not Available
Psychotic disorder19.03.01.002--
Exposure to noise12.03.05.001--Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.008--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Functional gastrointestinal disorder07.11.01.016--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages